686 related articles for article (PubMed ID: 30424953)
41. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
42. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
43. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
44. CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.
Chung JE; Magis W; Vu J; Heo SJ; Wartiovaara K; Walters MC; Kurita R; Nakamura Y; Boffelli D; Martin DIK; Corn JE; DeWitt MA
PLoS One; 2019; 14(1):e0208237. PubMed ID: 30645582
[TBL] [Abstract][Full Text] [Related]
45. Gesicle-Mediated Delivery of CRISPR/Cas9 Ribonucleoprotein Complex for Inactivating the HIV Provirus.
Campbell LA; Coke LM; Richie CT; Fortuno LV; Park AY; Harvey BK
Mol Ther; 2019 Jan; 27(1):151-163. PubMed ID: 30389355
[TBL] [Abstract][Full Text] [Related]
46. The Cas9 Hammer-and Sickle: A Challenge for Genome Editors.
Urnov FD
CRISPR J; 2021 Feb; 4(1):6-13. PubMed ID: 33616446
[TBL] [Abstract][Full Text] [Related]
47. Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia.
Xu S; Luk K; Yao Q; Shen AH; Zeng J; Wu Y; Luo HY; Brendel C; Pinello L; Chui DHK; Wolfe SA; Bauer DE
Blood; 2019 May; 133(21):2255-2262. PubMed ID: 30704988
[TBL] [Abstract][Full Text] [Related]
48. An Efficient Expression and Purification Protocol for SpCas9 Nuclease and Evaluation of Different Delivery Methods of Ribonucleoprotein.
Evmenov K; Pustogarov N; Panteleev D; Safin A; Alkalaeva E
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338898
[TBL] [Abstract][Full Text] [Related]
49. Gene Therapy Approaches to Hemoglobinopathies.
Ferrari G; Cavazzana M; Mavilio F
Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
[TBL] [Abstract][Full Text] [Related]
50. Construction of an Inducible CRISPR/Cas9 System for CXCR4 Gene and Demonstration of its Effects on MKN-45 Cells.
Peng Y; Yang T; Tang X; Chen F; Wang S
Cell Biochem Biophys; 2020 Mar; 78(1):23-30. PubMed ID: 31875277
[TBL] [Abstract][Full Text] [Related]
51. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
Hoban MD; Lumaquin D; Kuo CY; Romero Z; Long J; Ho M; Young CS; Mojadidi M; Fitz-Gibbon S; Cooper AR; Lill GR; Urbinati F; Campo-Fernandez B; Bjurstrom CF; Pellegrini M; Hollis RP; Kohn DB
Mol Ther; 2016 Sep; 24(9):1561-9. PubMed ID: 27406980
[TBL] [Abstract][Full Text] [Related]
52. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
Zhang S; Shen J; Li D; Cheng Y
Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
[TBL] [Abstract][Full Text] [Related]
53. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
[TBL] [Abstract][Full Text] [Related]
54. Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders.
Chen Y; Wen R; Yang Z; Chen Z
Gene Ther; 2022 May; 29(5):207-216. PubMed ID: 33750926
[TBL] [Abstract][Full Text] [Related]
55. CRISPR-Cas9 Editing of the
Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
[TBL] [Abstract][Full Text] [Related]
56. Efficient Genome Editing Achieved via Plug-and-Play Adenovirus Piggyback Transport of Cas9/gRNA Complex on Viral Capsid Surface.
Lu ZH; Li J; Dmitriev IP; Kashentseva EA; Curiel DT
ACS Nano; 2022 Jul; 16(7):10443-10455. PubMed ID: 35749339
[TBL] [Abstract][Full Text] [Related]
57. Electronic Circular Dichroism of the Cas9 Protein and gRNA:Cas9 Ribonucleoprotein Complex.
Halat M; Klimek-Chodacka M; Orleanska J; Baranska M; Baranski R
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805827
[TBL] [Abstract][Full Text] [Related]
58. Gene Therapy for β-Hemoglobinopathies.
Cavazzana M; Antoniani C; Miccio A
Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
[TBL] [Abstract][Full Text] [Related]
59. Gene Knockout in Hematopoietic Stem and Progenitor Cells Followed by Granulocytic Differentiation.
Mir P; Ritter M; Welte K; Skokowa J; Klimiankou M
Methods Mol Biol; 2020; 2115():455-469. PubMed ID: 32006417
[TBL] [Abstract][Full Text] [Related]
60. Preclinical evaluation for engraftment of CD34
Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
